Go back to school with your Mac, iPhone and TUAW

Note: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies, dial 911!

Posts with tag marketing

Massive ad campaign aims to lift lackluster Exubera sales

Remember back in 2006 all the buzz surrounding Exubera, Pfizer's inhalable insulin product? It was much-hyped by Pfizer and, let's face, the media happily joined in too, spreading the word that (as Pfizer would have it) Exubera would be wildly successful and make squillions of dollars for investors.

It didn't work out that way at all. Sales so far have topped out at around four million dollars per quarter, far short of the two billion projected before the product was released. Now, in a bid to lift lackluster sales, Pfizer is launching a major ad campaign for Exubera. Yes, the inhaler device is extremely indiscreet. Yes, long-term use of the drug itself could cause lung damage. Oh, and health insurers may not cover prescriptions for Exubera for those diabetics who want to try it. But I guess where there's a slick selling strategy there's a way...into the pockets of consumers, that is.

Which is not to say I blame Pfizer. The company has poured so much money into this product, does it really have a choice at this point? No. Also, it's entirely possible Pfizer could turn things around. This article by Arlene Weintraub for Business Week reminds readers that the drug giant had enormous success with its clever ad campaigns for Viagra and for the incontinence drug Detrol. Writes Weintraub, this new campaign will probably cost Pfizer big-time: we're talking tens of millions of dollars, but it will be worth it for Pfizer if it can reproduce that kind of success.

Novo asks you to aboutface

Meet the Face of Change is a photo exhibit owned by Novo Nordisk featuring YOU -- the face of change. Change for what, I asked? Well, it seems Novo would like to change your opinion of the barriers to insulin treatment for Type 2 diabetics. The common belief of insulin treatment for Type 2 diabetes is that it is the point of no return. Why? First instincts are usually correct.

Studies have shown that Type 2 diabetics injecting insulin create insulin antibodies (IAA). Type 1 diabetics have these antibodies upon diagnosis. Type 1 diabetes was also formerly referred to as insulin-dependent diabetes. Insulin antibodies (IAA) develop and attack the natural insulin produced, resulting in insulin dependence. Type 2 diabetics do not have the same level of IAA. Once they begin injecting insulin that looks like human insulin (the kind Novo makes) - you run the risk of developing IAA. The use of animal-insulins did not cause the development of IAA to the same extent. If you plan to start injecting insulin - ask your doctor if he will check you for IAA. As a Type 2 diabetic, you DO NOT have to become an insulin-dependent diabetic.

I asked Novo to explain what Meet the Face of Change is about. What are they trying to change? The response I received from Nov explains their wishes to strengthen the drive of their business, among other core values. Now I ask you - how do you drive a business that sells insulin? Sell more insulin. For the 16 million Type 2s not yet in this lineup- please consider if insulin-dependent diabetes is the face you want to meet. Don't add insulin to injury. It may not be the path of least resistance, but cut back on simple sugars, increase fiber consumption, and take a walk after dinner. Meet the face of change by putting your best foot forward, not your face on a campaign for vulture capitalism.

Snack food makers on the offensive

Say you're in the snack food business. Your products are popular amongst kids and adults alike. You rely on an arsenal of creative marketing to keep the money rolling in. Also, although your snack products are - when you get down to basics - really just reconstituted corn and its byproducts, they involve some pretty high-tech manufacturing techniques. So when the profitability of those products is threatened, you'd fight like the Dickens to protect yourself, wouldn't you?

That's exactly what's going on now, as manufacturers like Coca-Cola, Hershey, Kraft, Kellogg and Frito-Lay tweak their product lineup a little. Juuust enough, mind you, to meet criticism that they are contributing to the so-called obesity epidemic - and it's terrible health complications including heart disease and Type 2 diabetes - through peddling their fat and sugar-saturated products. As this AP article details, the snack food industry changes represent an attempt to, firstly, capitalize on the growing consumer demand for "healthy" food choices and, second, to undermine their critics (including those in government) who accuse them of direct responsibility for the health crisis.

From Kellogg to McDonald's, big business execs are scrambling to protect their companies: their brand image, their profitability, their investments and, yes, their employees. No, this is not really about the health of the nation or anything lofty like that. It's about cynically protecting the bottom line. Yet, strangely, I feel no sense of outrage about this. Can you blame them for giving just a little instead of a lot? What's more, while fatty snacks may be contributing to an overall decline in public health, I'd argue it's a step too far to compare the manufacturers to, say, the tobacco industry. After all, Fritos may be a nutritionist's nightmare but there's no addiction factor here to muddy the ethical waters. Nevertheless, given what happened to Big Tobacco, the snack food industry is taking no chances.

Features
Form and Function (12)
Retro Review (7)
Media
Personalities (38)
Blogs (21)
Books (24)
Products (129)
Services (43)
Magazines (12)
Meet the Bloggers
Bloggers (5)
Diane Rixon (1)
Chris Sparling (1)
Allie Beatty (38)
News
Daily News (180)
Events (63)
Fundraisers (23)
Opinion (114)
Prevention
Diet (366)
Exercise (97)
Lifestyle (512)
Research (465)
Treatment
Care (63)
Complications (37)
Drugs (384)
Support (235)
Types of Diabetes
Adult Onset (517)
Childhood (447)
Type 1 (791)
Type 2 (987)

RESOURCES

RSS NEWSFEEDS

Powered by Blogsmith

Other Weblogs Inc. Network blogs you might be interested in: